<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">bekhterev</journal-id><journal-title-group><journal-title xml:lang="ru">Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева</journal-title><trans-title-group xml:lang="en"><trans-title>V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7053</issn><issn pub-type="epub">2713-055X</issn><publisher><publisher-name>V. M. BEKHTEREV  NATIONAL  RESEARCH  MEDICAL  CENTER  FOR  PSYCHIATRY  AND  NEUROLOGY                           OF    THE  RUSSIAN  FEDERATION   MINISTRY  OF  HEALTH</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31363/2313-7053-2018-2-104-108</article-id><article-id custom-type="elpub" pub-id-type="custom">bekhterev-202</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GUIDELINES FOR THE PRACTITIONER</subject></subj-group></article-categories><title-group><article-title>Осложнения нейролептической гиперпролактинемии</article-title><trans-title-group xml:lang="en"><trans-title>Complications of neuroleptic hyperprolactinaemia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мазо</surname><given-names>Галина Элевна</given-names></name><name name-style="western" xml:lang="en"><surname>Mazo</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">galina-mazo@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горобец</surname><given-names>Людмила Николаевна</given-names></name><name name-style="western" xml:lang="en"><surname>Gorobets</surname><given-names>L. N.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">gorobetsln@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России, Санкт-Петербург</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V. M. Bekhterev National Research Medical Center For Psychiatry And Neurology Of Te Russian Federation Ministry Of Health, St.Petersburg</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский научно-исследовательский институт психиатрии (филиал ФГБУ «Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России), Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Research Institute of Psychiatry — branch of V.P. Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2018</year></pub-date><volume>0</volume><issue>2</issue><fpage>104</fpage><lpage>108</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мазо Г.Э., Горобец Л.Н., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Мазо Г.Э., Горобец Л.Н.</copyright-holder><copyright-holder xml:lang="en">Mazo G.E., Gorobets L.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.bekhterevreview.com/jour/article/view/202">https://www.bekhterevreview.com/jour/article/view/202</self-uri><abstract><p>В статье приводится обзор зарубежной и отечественной литературы в отношении проблемы развития осложнений, связанных с нейролептической гиперпролактинемией у больных шизофренического спектра в процессе длительной противорецидивной терапии антипсихотическими препаратами. Большинство исследователей сходятся во мнении, что длительно существующая нейролептическая гиперпролактинемия существенно ухудшает физическое здоровье больных с психическими расстройствами. Своевременная диагностика и коррекция указанного побочного эффекта психофармакотерапии значительно снизят риск развития осложнений и улучшит социальное функционирование больных с расстройствами шизофренического спектра.</p></abstract><trans-abstract xml:lang="en"><p>Te article provides an overview of foreign and domestic literature on the development of complications associated with neuroleptic hyperprolactinaemia in patients with schizophrenia in the course of prolonged antiretroviral therapy with antipsychotics. Most researchers agree that long-term neuroleptic hyperprolactinemia signifcantly impairs the physical health of patients with mental disorders. Timely diagnosis and correction of this side eﬀect of psychopharmacotherapy will signifcantly reduce the risk of complications and improve the social functioning of patients with schizophrenic disorders.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гиперпролактинемия</kwd><kwd>иммунная система</kwd><kwd>метаболические нарушения</kwd><kwd>остеопороз</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>когнитивные нарушения</kwd><kwd>онкологические заболевания.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hyperprolactinemia</kwd><kwd>immune system</kwd><kwd>metabolic disorders</kwd><kwd>osteoporosis</kwd><kwd>cardiovascular diseases</kwd><kwd>cognitive disorders</kwd><kwd>oncological diseases.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Горобец Л.Н., Поляковская Т.П., Литвинов А.В., Василенко Л.М., Буланов В.С. Проблема остеопороза у больных с психическими расстройствами при нейролептической терапии. Часть I // Социальная и клиническая психиатрия.—Том 22.—Выпуск 3.—2012.—С. 107-112.</mixed-citation><mixed-citation xml:lang="en">Горобец Л.Н., Поляковская Т.П., Литвинов А.В., Василенко Л.М., Буланов В.С. Проблема остеопороза у больных с психическими расстройствами при нейролептической терапии. Часть I // Социальная и клиническая психиатрия.—Том 22.—Выпуск 3.—2012.—С. 107-112.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Горобец Л.Н., Мазо Г.Э. Нейроэндокринные дисфункции при использовании психофармакотерапии: клиника, диагностика, факторы риска и коррекция // Журнал неврологии и психиатрии имени С.С.Корсакова. — 2014. — Том 114, №10. — С. 122-130.</mixed-citation><mixed-citation xml:lang="en">Горобец Л.Н., Мазо Г.Э. Нейроэндокринные дисфункции при использовании психофармакотерапии: клиника, диагностика, факторы риска и коррекция // Журнал неврологии и психиатрии имени С.С.Корсакова. — 2014. — Том 114, №10. — С. 122-130.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Горобец Л.Н., Мазо Г.Э. Гиперпролактинемия при использовании антипсихотиков второго поколения: принципы профилактики, диагностики и коррекции // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. — 2017. — №1. — С. 63-70.</mixed-citation><mixed-citation xml:lang="en">Горобец Л.Н., Мазо Г.Э. Гиперпролактинемия при использовании антипсихотиков второго поколения: принципы профилактики, диагностики и коррекции // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. — 2017. — №1. — С. 63-70.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. — М.: Триада-Х. — 2004.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. — М.: Триада-Х. — 2004.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Курляндская Р.И. Влияние гиперпролактинемии на основные показатели жирового обмена/ Р.И.Курляндская, Т.И.Романцова // Леч. врач. — 2004. — №1. — С. 6-9.</mixed-citation><mixed-citation xml:lang="en">Курляндская Р.И. Влияние гиперпролактинемии на основные показатели жирового обмена/ Р.И.Курляндская, Т.И.Романцова // Леч. врач. — 2004. — №1. — С. 6-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Мазо Г.Э. Перспективы развития эндокринологической психиатрии / Современные достижения в диагностике и лечении эндогенных расстройств. Сборник научных трудов. Серия «Современная психоневрология». СанктПетербург, 2008. С. 210-224.</mixed-citation><mixed-citation xml:lang="en">Мазо Г.Э. Перспективы развития эндокринологической психиатрии / Современные достижения в диагностике и лечении эндогенных расстройств. Сборник научных трудов. Серия «Современная психоневрология». СанктПетербург, 2008. С. 210-224.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Пирматова М.А., Анварова Ш.С., Ниязова Н.Ф. К вопросу о нарушении жиро-углеводного обмена у больных с синдромом гиперпролактинемии // Международный научно-исследовательский журнал. Медицинские науки.—2016.—№ 7 (49), часть 3.—С. 85-90.</mixed-citation><mixed-citation xml:lang="en">Пирматова М.А., Анварова Ш.С., Ниязова Н.Ф. К вопросу о нарушении жиро-углеводного обмена у больных с синдромом гиперпролактинемии // Международный научно-исследовательский журнал. Медицинские науки.—2016.—№ 7 (49), часть 3.—С. 85-90.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Чуршин А.Д. Клинико-функциональные и метаболические характеристики ишемической болезни сердца у женщин и дифференцированная терапия. Дисс. … докт. мед. наук. 2009.</mixed-citation><mixed-citation xml:lang="en">Чуршин А.Д. Клинико-функциональные и метаболические характеристики ишемической болезни сердца у женщин и дифференцированная терапия. Дисс. … докт. мед. наук. 2009.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bushe C., Shaw M., Peveler R. A review of the association between antipsychotic use and hyperprolactinaemia. — J. Psy- chopharmacol. — 2008. — Vol.22. — P.46-55.</mixed-citation><mixed-citation xml:lang="en">Bushe C., Shaw M., Peveler R. A review of the association between antipsychotic use and hyperprolactinaemia. — J. Psy- chopharmacol. — 2008. — Vol.22. — P.46-55.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bushe C., Bradley A., Pendlebury J. A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry? // Ann. Clin. Biochem. — 2010. — Vol. 47. — Р.292-300.</mixed-citation><mixed-citation xml:lang="en">Bushe C., Bradley A., Pendlebury J. A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry? // Ann. Clin. Biochem. — 2010. — Vol. 47. — Р.292-300.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">BusheC., Hodgson R. Schizophrenia and cancer: in 2010 do we understand the connection? — Can. J. Psychiatry. — 2010. — Vol.55. — P. 761-767.</mixed-citation><mixed-citation xml:lang="en">BusheC., Hodgson R. Schizophrenia and cancer: in 2010 do we understand the connection? — Can. J. Psychiatry. — 2010. — Vol.55. — P. 761-767.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Catts V.S., Catts S.V., O’Toole B.I., Frost A.D. Cancer incidence in patients with schizophrenia and their frst-degree relatives−a meta-analysis. — Acta Psychiatr. Scand. — 2008. — Vol.117. — P. 323-336.</mixed-citation><mixed-citation xml:lang="en">Catts V.S., Catts S.V., O’Toole B.I., Frost A.D. Cancer incidence in patients with schizophrenia and their frst-degree relatives−a meta-analysis. — Acta Psychiatr. Scand. — 2008. — Vol.117. — P. 323-336.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cookson J., Hodgson R., Hiram J.W. Prolactin, hyperpro- lactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. — J. Psychopharmacol. — 2012. — Vol.26. — P.42-51.</mixed-citation><mixed-citation xml:lang="en">Cookson J., Hodgson R., Hiram J.W. Prolactin, hyperpro- lactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. — J. Psychopharmacol. — 2012. — Vol.26. — P.42-51.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">De Bellis A., Bizzarro A., Pivonello R., Lombardi G., Bellastella A. Prolactin and autoimmunity. — Pituitary. — 2005. — Vol.8. — P.25-30.</mixed-citation><mixed-citation xml:lang="en">De Bellis A., Bizzarro A., Pivonello R., Lombardi G., Bellastella A. Prolactin and autoimmunity. — Pituitary. — 2005. — Vol.8. — P.25-30.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">DeHert M., Peuskens J., Sabbe T. et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. — Acta Psychiatr. Scand. — 2016. — Vol.133. — P.5-22.</mixed-citation><mixed-citation xml:lang="en">DeHert M., Peuskens J., Sabbe T. et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. — Acta Psychiatr. Scand. — 2016. — Vol.133. — P.5-22.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dorshkind K., Horseman N.. Te roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor defciency. — Endocr. Rev. — 2000. — Vol.21. — P.292-312.</mixed-citation><mixed-citation xml:lang="en">Dorshkind K., Horseman N.. Te roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor defciency. — Endocr. Rev. — 2000. — Vol.21. — P.292-312.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fan Z., Wu Y.,Shen J., Ji T., Zhan R. Schizophrenia and the risk of cardiovascular diseases:a meta-analysis of thirteen cohort studies. — J Psychiatr Res. — 2013. — Vol.47. — P.1549-1556.</mixed-citation><mixed-citation xml:lang="en">Fan Z., Wu Y.,Shen J., Ji T., Zhan R. Schizophrenia and the risk of cardiovascular diseases:a meta-analysis of thirteen cohort studies. — J Psychiatr Res. — 2013. — Vol.47. — P.1549-1556.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fahy U., Hopton M.I., Hartog M., Bolton C.H., Hull M.G. Te lipoprotein profle of women with hyperprolactinaemic amenorrhoea // Hum. Reprod. - 1999. — Vol.14. — P.285-287.</mixed-citation><mixed-citation xml:lang="en">Fahy U., Hopton M.I., Hartog M., Bolton C.H., Hull M.G. Te lipoprotein profle of women with hyperprolactinaemic amenorrhoea // Hum. Reprod. - 1999. — Vol.14. — P.285-287.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Freeman M.E., Kanyicska B., Lerant A., Nagy G. Prolactin: structure, function and regulation of secretion. — Physiol Rev. — 2000. — Vol.80. — P.1523- 1631.</mixed-citation><mixed-citation xml:lang="en">Freeman M.E., Kanyicska B., Lerant A., Nagy G. Prolactin: structure, function and regulation of secretion. — Physiol Rev. — 2000. — Vol.80. — P.1523- 1631.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation // CNS Drugs. — 2007. — Vol.21, № 8. — Р.641-657.</mixed-citation><mixed-citation xml:lang="en">Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation // CNS Drugs. — 2007. — Vol.21, № 8. — Р.641-657.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Henry J.F., Sherwin B.B. Hormones and cognitive functioning during late pregnancy and postpartum: a longitudinal study. — Behav. Neurosci. — 2012. — Vol.126. — P.73-85.</mixed-citation><mixed-citation xml:lang="en">Henry J.F., Sherwin B.B. Hormones and cognitive functioning during late pregnancy and postpartum: a longitudinal study. — Behav. Neurosci. — 2012. — Vol.126. — P.73-85.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hofauer L.C., Hamann Ch., Ebeling P.R. Approach to the patient with secondary osteoporosis // Eur. J. Endocrinol. — 2010. — Vol.162. — Р.1009 — 1020.</mixed-citation><mixed-citation xml:lang="en">Hofauer L.C., Hamann Ch., Ebeling P.R. Approach to the patient with secondary osteoporosis // Eur. J. Endocrinol. — 2010. — Vol.162. — Р.1009 — 1020.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Holt R.I., Hanley N.A. Summary of the regulation and effects of prolactin. In Chapter 5: Te hypothalamus and pituitary gland. — Essential Endocrinology: Blackwell Publishing. — 2006. -66p.</mixed-citation><mixed-citation xml:lang="en">Holt R.I., Hanley N.A. Summary of the regulation and effects of prolactin. In Chapter 5: Te hypothalamus and pituitary gland. — Essential Endocrinology: Blackwell Publishing. — 2006. -66p.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Howard L., Kirkwood G., Leesem O. Risk of hip fracture in patients with a history of schizophrenia // Te British Journal of Psychiatry. — 2007. — Vol.190. — Р.129 — 134.</mixed-citation><mixed-citation xml:lang="en">Howard L., Kirkwood G., Leesem O. Risk of hip fracture in patients with a history of schizophrenia // Te British Journal of Psychiatry. — 2007. — Vol.190. — Р.129 — 134.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hummer M., Malik P., Gasser R.W. et al. Osteoporosis in patients with schizophrenia//Am J Psychiatry. — 2005. — Vol.162, № 1. — Р.162-167.</mixed-citation><mixed-citation xml:lang="en">Hummer M., Malik P., Gasser R.W. et al. Osteoporosis in patients with schizophrenia//Am J Psychiatry. — 2005. — Vol.162, № 1. — Р.162-167.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ignacak A., Kasztelnik M., Sliwa T., Korbut R., Rajda K., Guzik T. Prolactin not only lactotrophin. A ‘‘new’’ view of the ‘‘old’’ hormone. — J. Physiol. Pharmacol. — 2012. — Vol.63. — P.435-443.</mixed-citation><mixed-citation xml:lang="en">Ignacak A., Kasztelnik M., Sliwa T., Korbut R., Rajda K., Guzik T. Prolactin not only lactotrophin. A ‘‘new’’ view of the ‘‘old’’ hormone. — J. Physiol. Pharmacol. — 2012. — Vol.63. — P.435-443.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia. — Aust. NZ — J. Psychiatry. — 2011. — Vol.45. — P.830-837.</mixed-citation><mixed-citation xml:lang="en">Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia. — Aust. NZ — J. Psychiatry. — 2011. — Vol.45. — P.830-837.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Jablensky A., Lawrence D. Schizophrenia and cancer: is there a need to invoke a protective gene? — Arch. Gen. Psychiatry. — 2001. — Vol.58. — P.579-580.</mixed-citation><mixed-citation xml:lang="en">Jablensky A., Lawrence D. Schizophrenia and cancer: is there a need to invoke a protective gene? — Arch. Gen. Psychiatry. — 2001. — Vol.58. — P.579-580.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Laita P., Cifuentes A., Doll A., Llorente C., Cortés I., Parellada M. et al. Antipsychotic-related abnormal involuntary movements and meta-bolic and endocrine side eﬀects in children and adolescents. — J. Child. Adolesc. Psychopharmacol. — 2007. — Vol.17. — P.487-502.</mixed-citation><mixed-citation xml:lang="en">Laita P., Cifuentes A., Doll A., Llorente C., Cortés I., Parellada M. et al. Antipsychotic-related abnormal involuntary movements and meta-bolic and endocrine side eﬀects in children and adolescents. — J. Child. Adolesc. Psychopharmacol. — 2007. — Vol.17. — P.487-502.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y.H., Bae S.C., Song G.G. Meta-analysis of associations between functional prolactin -1149 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus. — Clin Rheumatol. - 2015. — Vol.34. — P.683-690. doi: 10.1007/s10067-015-2904-3. Epub 2015 Feb 28.</mixed-citation><mixed-citation xml:lang="en">Lee Y.H., Bae S.C., Song G.G. Meta-analysis of associations between functional prolactin -1149 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus. — Clin Rheumatol. - 2015. — Vol.34. — P.683-690. doi: 10.1007/s10067-015-2904-3. Epub 2015 Feb 28.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Li M., Fan Y.L., Tang Z.Y., Cheng X.S. Schizophrenia and risk of stroke: a meta-analysis of cohort studies.—Int. J. Cardiol.—2014.—Vol.173.—P.588-590.</mixed-citation><mixed-citation xml:lang="en">Li M., Fan Y.L., Tang Z.Y., Cheng X.S. Schizophrenia and risk of stroke: a meta-analysis of cohort studies.—Int. J. Cardiol.—2014.—Vol.173.—P.588-590.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuda M., Mori T., Sassa S. et al. Chronic effect of hyperprolactinemia on blood glucose and lipid levels in mice // Life Sciences. — 1996. - Vol.58. – Р.1171-1177.</mixed-citation><mixed-citation xml:lang="en">Matsuda M., Mori T., Sassa S. et al. Chronic effect of hyperprolactinemia on blood glucose and lipid levels in mice // Life Sciences. — 1996. - Vol.58. – Р.1171-1177.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Meaney A.M., Smith S., Howes O.D. et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia // Br. J.Psychiatry. — 2004. — Vol.184. — Р.503–508.</mixed-citation><mixed-citation xml:lang="en">Meaney A.M., Smith S., Howes O.D. et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia // Br. J.Psychiatry. — 2004. — Vol.184. — Р.503–508.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Melmed S, Casanueva FF, Hoﬀman RA, Kleinberg LD, Montori MV, Schlechte AJ, et al., Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. — J. Clin. Endocrinol. Metab. — 2011. — Vol.96. — P.273-288.</mixed-citation><mixed-citation xml:lang="en">Melmed S, Casanueva FF, Hoﬀman RA, Kleinberg LD, Montori MV, Schlechte AJ, et al., Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. — J. Clin. Endocrinol. Metab. — 2011. — Vol.96. — P.273-288.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Misra M., Papakostas G. I., Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism // Journal of Clinical Psychiatry.—2004.—Vol. 65. –Р.1607-1618.</mixed-citation><mixed-citation xml:lang="en">Misra M., Papakostas G. I., Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism // Journal of Clinical Psychiatry.—2004.—Vol. 65. –Р.1607-1618.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Moﬀat S.D., Zonderman A.B., Metter E.J., Blackman M.R., Harman S.M., Resnick S.M. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. — J. Clin. Endocrinol. Metab. — 2002. — Vol.87. — P.5001-5007.</mixed-citation><mixed-citation xml:lang="en">Moﬀat S.D., Zonderman A.B., Metter E.J., Blackman M.R., Harman S.M., Resnick S.M. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. — J. Clin. Endocrinol. Metab. — 2002. — Vol.87. — P.5001-5007.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Moﬀat S.D., Zonderman A.B., Metter E.J., Kawas C., Blackman M.R., Harman S.M. et al. Free testosterone and risk for Alzheimer disease in older men. — Neurology. — 2004. — Vol.62. — P.188-193.</mixed-citation><mixed-citation xml:lang="en">Moﬀat S.D., Zonderman A.B., Metter E.J., Kawas C., Blackman M.R., Harman S.M. et al. Free testosterone and risk for Alzheimer disease in older men. — Neurology. — 2004. — Vol.62. — P.188-193.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Morris A. Diabetes: linking diabetes and schizophrenia. — Nat. Rev. Endocrinol. — 2017. — Vol.13. — P. 126.</mixed-citation><mixed-citation xml:lang="en">Morris A. Diabetes: linking diabetes and schizophrenia. — Nat. Rev. Endocrinol. — 2017. — Vol.13. — P. 126.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">O’Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? — J. Clin. Psychopharmacol. — 2005. — Vol.25. — P.26-31.</mixed-citation><mixed-citation xml:lang="en">O’Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? — J. Clin. Psychopharmacol. — 2005. — Vol.25. — P.26-31.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia //J.Psychopharmacol. — 2008. — Vol.22. — Р.70-75.</mixed-citation><mixed-citation xml:lang="en">O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia //J.Psychopharmacol. — 2008. — Vol.22. — Р.70-75.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Orbach H., Shoenfeld Y. Hyperprolactinemia and autoimmune diseases // Autoimmun. Rev. — 2007. — Vol.6. — P.537-542.</mixed-citation><mixed-citation xml:lang="en">Orbach H., Shoenfeld Y. Hyperprolactinemia and autoimmune diseases // Autoimmun. Rev. — 2007. — Vol.6. — P.537-542.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Orbetzova MM1, Kamenov ZA, Kolarov GB, Orbetzova VT, Genchev GD, Genov NS, Zacharieva SZ. Metabolic disturbances in women with polycystic ovary syndrome. — Folia Med (Plovdiv). – 2003. — Vol.45. — P.12-20.</mixed-citation><mixed-citation xml:lang="en">Orbetzova MM1, Kamenov ZA, Kolarov GB, Orbetzova VT, Genchev GD, Genov NS, Zacharieva SZ. Metabolic disturbances in women with polycystic ovary syndrome. — Folia Med (Plovdiv). – 2003. — Vol.45. — P.12-20.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Seeman M.V. Women at Greater Risk Tan Men //Schizophr Bull. — 2009. — Vol.35. — Р.937 — 948.</mixed-citation><mixed-citation xml:lang="en">Seeman M.V. Women at Greater Risk Tan Men //Schizophr Bull. — 2009. — Vol.35. — Р.937 — 948.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Seriwatanachai D., Krishnamra N., van Leeuwen J.P. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization // J. Cell. Biochem. — 2009. — 107. — Р.677- 685.</mixed-citation><mixed-citation xml:lang="en">Seriwatanachai D., Krishnamra N., van Leeuwen J.P. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization // J. Cell. Biochem. — 2009. — 107. — Р.677- 685.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Takkouche B., Montes-Martinez A., Gill S.S. et al. Psychotropic medications and the risk of fractures: a meta-analysis // Drug. Saf. — 2007. — Vol.30. — P. 171–184.</mixed-citation><mixed-citation xml:lang="en">Takkouche B., Montes-Martinez A., Gill S.S. et al. Psychotropic medications and the risk of fractures: a meta-analysis // Drug. Saf. — 2007. — Vol.30. — P. 171–184.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Vancampfort D., Correll C.U., Galling B. et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis // World Psychiatry. — 2016. — Vol.15. — P. 166-174.</mixed-citation><mixed-citation xml:lang="en">Vancampfort D., Correll C.U., Galling B. et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis // World Psychiatry. — 2016. — Vol.15. — P. 166-174.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Wang M. et al. Circulating prolactin associates with diabetes and impaired glucose regulation // Diabetes Care. — 2013. — Vol.36. — P.1974-1980.</mixed-citation><mixed-citation xml:lang="en">Wang M. et al. Circulating prolactin associates with diabetes and impaired glucose regulation // Diabetes Care. — 2013. — Vol.36. — P.1974-1980.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Wang M., Wu X., Chai F., Zhang Y., Jiang J. Plasma prolactin and breast cancer risk: a metaanalysis. — Sci Rep. — 2016. — Vol.6. — P.259-298.</mixed-citation><mixed-citation xml:lang="en">Wang M., Wu X., Chai F., Zhang Y., Jiang J. Plasma prolactin and breast cancer risk: a metaanalysis. — Sci Rep. — 2016. — Vol.6. — P.259-298.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Zhuo Ch., Triplett P. T. Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis. — JAMA Psychiatry. - 2018. — Vol.75. — P.363- 369. doi:10.1001/jamapsychiatry.2017.4748.</mixed-citation><mixed-citation xml:lang="en">Zhuo Ch., Triplett P. T. Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis. — JAMA Psychiatry. - 2018. — Vol.75. — P.363- 369. doi:10.1001/jamapsychiatry.2017.4748.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
